TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03904524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SET-to-Meet
Description: The overall objective of this study is to pilot test, in advance of a larger randomized trial, a scalable, nurse-led intervention to ensure timely interdisciplinary family meetings are held on behalf of critically-ill ICU patients who cannot participate in discussions about their care.
Study: NCT03032081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: High intensity exercise, defined as an exercise intensity of \> 80% of heart rate reserve. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise
Description: Moderate intensity exercise, defined as 50 to 60% of heart rate reserve for 40 to 47 minutes per day, 4 days per week, for 8 weeks. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
Study: NCT02974387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorometholone(FML)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol (Lotemax)
Study: NCT01955850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for insomnia
Description: Cognitive behavioral treatment for insomnia, consisting of: psycho-education, sleep hygiene, stimulus control, sleep restriction, cognitive therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for insomnia
Description: Cognitive behavioral treatment for insomnia, consisting of: psycho-education, sleep hygiene, stimulus control, sleep restriction, cognitive therapy.
Study: NCT04171648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roasted Peanut Treatment
Description: The subjects will consume 2 ounces or \~48 grams of roasted in shell peanuts a day for two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roasted Peanut Treatment
Description: The subjects will consume 2 ounces or \~48 grams of roasted in shell peanuts a day for two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Peanut Treatment
Description: The subjects will consume 2 ounces or \~48 grams of boiled peanuts a day for two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Peanut Treatment
Description: The subjects will consume 2 ounces or \~48 grams of boiled peanuts a day for two weeks.
Study: NCT02946541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evogliptin 5mg
Description: evogliptin 5mg, QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, QD
Study: NCT01797965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab)
Description: Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
Study: NCT01705197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avanafil 100 or 200mg
Description: This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avanafil 100 or 200mg
Description: This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
Study: NCT03265639

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P-inulin
Study: NCT00860483

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: observational
Description: PET Scan
Study: NCT03556735

Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment with PEMF equipment
Description: Treatment with PEMF in 8 weeks
Study: NCT05800106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate capsules generic product
Description: Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib malate capsules reference product
Description: Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
Study: NCT02695524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapula-focused exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scapula-focused exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor control exercises
Study: NCT03484351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall Monty Activity Programme (FallMAP)
Description: The programme delivered during this feasibility study will consist of a total of 12 multifactorial falls prevention group exercise sessions of 90-100 minutes in duration, followed by a 20-30 minute social activity. The sessions will be offered over a period of 8 weeks. Each session will comprise (a mix of) seven program components of the intervention: 1) falls prevention education, 2) FaME group-based exercises for strength and dynamic balance, 3) (Preparing for) home exercises, 4) Interactive, virtual reality gamefied exercises, 5) Getting on and off the floor / floorwork / safe landing \& falls technique activities, 6) Home falls hazard evaluation and 7) A social activity after the exercise session.
Study: NCT01881971

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: suger pill manufactured to mimic crestor pills
Study: NCT00976456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab + Pemetrexed
Description: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
Study: NCT01881971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rouvastatin calcium
Study: NCT00976456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab + Pemetrexed + Carboplatin
Description: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
Study: NCT01528020

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual and Group Supportive Therapy
Description: The aim of IGST is relief or reduction of symptoms, the promotion of personal growth including enhancement of adolescents' strengths/coping skills and capacity to use environmental supports and to help suicidal adolescents increase their sense of self-esteem. Treatment aims to reduce suicidal behavior and emotion dysregulation by helping the adolescent learn to trust and validate themselves. The overarching assumption in IGST is that adolescents become suicidal for a variety of reasons, but they often report feeling isolated, misunderstood, unloved and unwanted. IGST Interventions include providing a strong therapeutic alliance where the therapist provides an environment that is completely trusting and validating to counter the experience of the depressed/suicidal youth.
Study: NCT02283450

Intervention type: DRUG
Intervention: Qiliqiangxin Capsule

Intervention type: DRUG
Intervention: Qiliqiangxin Capsule
Study: NCT01613950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
Study: NCT03367325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDS-NVAF
Description: The CDS-NVAF is intended for patients diagnosed with NVAF and treated with VKA. This tool calculates the time in the therapeutic range (TTR) using the Rosendaal method considering the last International Normalized Ratio (INR) data. The INR data are found in the clinical history of NVAF patients. The CDS-NVAF will be activated when the physician introduces the last INR value. At this time the TTR will be calculated automatically. If the TTR value is \< 65%, a pop up screen with a warning text will open suggesting a change to DOAC therapy. The physician can decide whether to change or not the previous prescription. If the TTR value in \> 65% the pop up screen will not appear. The TTR value will remain registered on the screen of the follow up of oral anticoagulant use and can be consulted in future queries. The diffusion of the CDS-NVAF will be made by an announcement on the first day of the intervention when the health care professional opens the electronic clinical history.
Study: NCT02407171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: 200 mg every 2 weeks by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: 200 mg every 2 weeks by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: 200 mg every 2 weeks by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: 200 mg every 2 weeks by IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
Study: NCT04741906

Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Dental surgery in patients treated with antiresorptive medication

Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Dental surgery in patients treated with antiresorptive medication

Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Dental surgery in patients treated with antiresorptive medication

Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Dental surgery in patients treated with antiresorptive medication

Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Dental surgery in patients treated with antiresorptive medication

Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Dental surgery in patients treated with antiresorptive medication

Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Dental surgery in patients treated with antiresorptive medication

Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Dental surgery in patients treated with antiresorptive medication

Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Dental surgery in patients treated with antiresorptive medication

Intervention type: PROCEDURE
Intervention: Prosthetic treatment
Description: Prosthetic treatment and loading of the dental implants

Intervention type: PROCEDURE
Intervention: Prosthetic treatment
Description: Prosthetic treatment and loading of the dental implants

Intervention type: PROCEDURE
Intervention: Prosthetic treatment
Description: Prosthetic treatment and loading of the dental implants

Intervention type: PROCEDURE
Intervention: Prosthetic treatment
Description: Prosthetic treatment and loading of the dental implants

Intervention type: PROCEDURE
Intervention: Prosthetic treatment
Description: Prosthetic treatment and loading of the dental implants

Intervention type: PROCEDURE
Intervention: Prosthetic treatment
Description: Prosthetic treatment and loading of the dental implants

Intervention type: PROCEDURE
Intervention: Prosthetic treatment
Description: Prosthetic treatment and loading of the dental implants

Intervention type: PROCEDURE
Intervention: Prosthetic treatment
Description: Prosthetic treatment and loading of the dental implants

Intervention type: PROCEDURE
Intervention: Prosthetic treatment
Description: Prosthetic treatment and loading of the dental implants
Study: NCT02417467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine E-Cigarette

Intervention type: OTHER
Group type: OTHER
Intervention: Non-Nicotine E-Cigarette

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Study: NCT01743872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast Injection
Description: Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dextran Injection
Description: Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 Injection
Description: Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heparinized Normal Saline Injection
Description: Media #4: Heparinized Normal Saline (Heparin NS) will be hand injected using 20 mL (2 U/mL) in antegrade fashion.
Study: NCT01206478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Amitriptyline 1 mg/kg once daily at bedtime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (looks like study drug but has no active ingredients) once daily at bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol
Description: At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol
Description: At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
Study: NCT04205968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV bolus or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study: NCT02407171

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
Study: NCT02658513

Intervention type: OTHER
Intervention: Lancet blood sampling
Description: Blood samples will be obtained using a finger-prick (lancet) technique.

Intervention type: OTHER
Intervention: Standard intravenous blood sampling
Description: Blood samples will be obtained using a standard intravenous technique.
Study: NCT03250299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microtubule-Targeted Agent BAL101553
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT02334111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESPECT-Plus
Description: A RESPECT-Plus family specialist (FS) will deliver the intervention to subjects (mothers in treatment for opiate use disorder) recruited during their third trimester of pregnancy and randomized into the study's intervention arm post-delivery. During their infant's hospital stay, the FS will schedule a convenient time to meet the subjects (mothers) to educate them on infant soothing techniques. With permission from the mother, the FS will join the subjects during their infant's routine well-child visits at the pediatric primary site. Optional home visiting provides another meeting opportunity between the subjects and FS.
Study: NCT02519621

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT PRO without irrigation
Description: NPWT PRO without irrigation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT PRO with irrigation
Description: NPWT PRO with irrigation (saline)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KCI Ulta
Description: KCI Ulta NPWT without irrigation
Study: NCT02744131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1500mgs per day
Study: NCT01712919

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Patients will be given intensity-modulated radiotherapy(IMRT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy with paclitaxel and nedaplatin
Description: Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Patients will be given cetuximab weekly during radiation therapy
Study: NCT03295695

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluoro-D-glucose-positron Emission Tomography
Description: 2-deoxy-2-\[18F\]Fluoro-D-glucose-positron Emission Tomography (FDG-PET): within 2 weeks of obtaining first echocardiogram; within two weeks of obtaining follow-up echocardiogram.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-deoxy-2-[18F]fluoro-D-glucose (FDG)
Description: 2-deoxy-2-\[18F\]fluoro-D-glucose (FDG) labeled autologous human erythrocytes (RBCs): Approximately 10 mls of packed human erythrocytes are collected from the patient and labeled with ≈5-10 milliCuries of commercially available United States Pharmacopeia (USP)-grade FDG (≈5-10 picograms FDG) (Vendor: Cardinal Health) under sterile conditions in a Good Manufacturing Practice (GMP)-certified laboratory.~Synthesized RBCs: The cell suspension is manually infused via syringe through an indwelling peripheral venous catheter over the course of 1 minute, using an infusion method approved by the Moffitt Cancer Center (MCC) radiation safety officer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: Echocardiogram: prior to start of chemotherapy; post-treatment regimen.
Study: NCT03336957

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal treatment
Description: non-surgical periodontal therapy (NPT) consisted of scaling, root planning, and oral hygiene instruction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal treatment
Description: non-surgical periodontal therapy (NPT) consisted of scaling, root planning, and oral hygiene instruction
Study: NCT00062751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole / Temsirolimus (CCI-779)
Description: Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole / Temsirolimus (CCI-779)
Description: Letrozole 2.5 mg daily + Temsirolimus (CCI-779) intermittent 30 mg daily for five days every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 mg daily
Study: NCT01427166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non invasive venous ultrasound
Description: Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
Study: NCT04519970

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: Each tier will have a different level of case management and support, all with the goal of increasing adherence to Biktarvy for HIV management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: Each tier will have a different level of case management and support, all with the goal of increasing adherence to Biktarvy for HIV management.
Study: NCT00214266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath 1H®, Rituximab, mycophenolate mofetil
Description: Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
Study: NCT01230736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)
Description: One drop in study eye(s) once daily for 8 weeks